Novartis Lifts Core Profit Outlook After Third-Quarter Core EPS Rises 9% To $2.46
The drugmaker now expects 2026 core operating income to hold flat or grow slightly, even as a $1.9 billion write-down hit reported profit.
Novartis, the Swiss medicines company, raised its 2026 outlook for core operating income on Tuesday after third-quarter core EPS rose 9% to $2.46, or 8% at constant currencies. Reported operating income fell 59% to $1.8 billion, weighed by a $1.9 billion partial write-down of its del-desiran asset.
Core margin widens, guidance moves up
Net sales rose 4% to $14.5 billion in the quarter, in both U.S. dollars and constant currencies. Core operating income, an adjusted measure, reached $6.0 billion, up 11% (10% at constant currencies), and the core margin was 41.6%, up 2 percentage points at constant currencies.
For the full year, Novartis now expects core operating income to be in line with last year or grow low single digits at constant currencies. It previously guided to a low single-digit decline. The net sales outlook of low single-digit growth is unchanged.
CEO Vas Narasimhan said priority brands and launches "more than offset generic erosion." Kisqali rose 37% at constant currencies, Kesimpta 22%, Scemblix 67%, Leqvio 63% and Cosentyx 9%. Entresto fell 38%.
Volume added 14 percentage points to sales growth, while generic competition took away 9 points and pricing cost 1 point.
A $1.9 billion write-down and two trial misses
Operating income fell mainly on higher research spending, including the $1.9 billion partial impairment of the del-desiran research asset, and on higher other expense. Net income fell 70% to $1.2 billion, and EPS was $0.63 against $2.04 a year earlier.
In the same release, Novartis said the Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 missed its main goal, and that it will engage health authorities on a development path. Narasimhan said the readout "was not what we had hoped" but showed evidence of clinical activity. Pelacarsen also missed its main goal in the Phase III HORIZON trial in patients with elevated Lp(a) and established cardiovascular disease.
On the positive side, remibrutinib succeeded in two Phase III trials in relapsing multiple sclerosis, and the FDA expanded Rhapsido's use and approved Pluvicto in an earlier prostate cancer setting.
Cash flow and a higher debt load
Free cash flow was $5.1 billion in the quarter, down 18%, on lower operating cash flows. For the first nine months it was $14.0 billion, down 12%.
Net debt stood at $37.4 billion on September 30, 2026, up from $21.9 billion at the end of 2025. The company cited $16.7 billion of outflows for acquisitions and intangible assets, a $9.1 billion dividend and $4.8 billion of treasury share transactions, which more than offset free cash flow.
In the first nine months, Novartis bought back 30.9 million shares for $4.7 billion. Up to $4.9 billion remains under its $10 billion buyback announced in July 2025.
Novartis will report fourth-quarter and full-year results on February 3, 2027, and hold its annual meeting on March 5, 2027, where the board will nominate former Microsoft executive Rajesh Jha for election.
Sources
- Form 6-K — 99.1 FINANCIAL REPORT Q3 2026 — SEC EDGAR
- Novartis Already Paid for Its $1.9 Billion Write-Down. The Raise Is the New Part — Yahoo Finance
- Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside — Yahoo Finance
- Novartis : le BPA ajusté du T3 à 2,46 $ dépasse l’estimation de 2,27 $, les ventes à 14,522 milliards $ manquent l’estimation de 14,582 milliards $1 min de lecture — fr.benzinga.com